18 Jan Luminary Therapeutics
Jeff Liter, CEO
Minneapolis, MN
(Private)
Luminary Therapeutics is a clinical-stage biotechnology company developing next-generation CAR T-cell therapies that integrate advanced CAR engineering, novel targets and proprietary manufacturing innovations to create durable, transformative treatments that could become broadly accessible to patients with cancer and autoimmune diseases. Luminary’s lead program features a multi-antigen targeting BAFF ligand CAR designed to overcome tumor escape pathways and achieve robust B-cell depletion, including long-lived plasma B cells. Lead product, LMY-920 is an autologous BAFF-CAR T-cell therapy currently in Phase 1 clinical trials for NHL and MM, with planned expansion into CLL and lupus and rheumatoid arthritis. Second product, LMY-932, is an allogeneic BAFF-CAR T-cell therapy, engineered on a gamma-delta chassis for improved tumor homing and safety, expected to enter clinical trials in hematologic cancers and autoimmune diseases in 2026. Additionally, Luminary’s second program is developing gamma-delta T cells engineered with dual-targeting CARs for enhanced safety and broad applicability across solid tumors.
